Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Which groups might Boston Scientific bolt on next?
Sequencing data is all well and good, but what does it mean?
Bayer's only remaining medical technology franchise is its radiology business.
Regulatory intervention having limited impact on fostering innovation.
Nine IPOs have got away so far this year, and one of them is very big indeed.
A return to tuck-in deals – sort of.